Search Results - "Chandhasin, Chandtip"

Targeting the N‐Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer by Antonarakis, Emmanuel S., Chandhasin, Chandtip, Osbourne, Erica, Luo, Jun, Sadar, Marianne D., Perabo, Frank

“…Despite the recent approval and widespread use of abiraterone acetate and enzalutamide for the treatment of castration‐resistant prostate cancer (CRPC), this…”
Get full text

TACH101, a first-in-class pan-inhibitor of KDM4 for treatment of gastrointestinal cancers by Perabo, Frank, Chandhasin, Chandtip, Yoo, Sanghee, Dang, Van, Del Rosario, Joselyn, Chen, Young K, Stafford, Jeffrey, Quake, Stephen, Clarke, Michael F.

“…Abstract only 132 Background: TACH101 is a novel, potent small molecule inhibitor of KDM4, a novel epigenetic target for cancer therapy. KDM4 is a family of…”
Get full text

Building an External Control Arm for Development of a New Molecular Entity: An Application in a Recurrent Glioblastoma Trial for MDNA55 by Majumdar, Antara, Davi, Ruthanna, Bexon, Martin, Chandhasin, Chandtip, Coello, Melissa, Merchant, Fahar, Merchant, Nina

“…In certain indications, it is well understood that randomized controlled trials lead to slow enrollment and high differential drop-out rate in the standard of…”
Get full text

Human T-Cell Leukemia Virus Type 1 Tax Attenuates the ATM-Mediated Cellular DNA Damage Response by CHANDHASIN, Chandtip, DUCU, Razvan I, BERKOVICH, Elijahu, KASTAN, Michael B, MARRIOTT, Susan J

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Prevalence of complementary medicine use in a phase 1 clinical trials program by Naing, Aung, Stephen, Saneese K., Frenkel, Moshe, Chandhasin, Chandtip, Hong, David S., Lei, Xiudong, Falchook, Gerald, Wheler, Jennifer J., Fu, Siqing, Kurzrock, Razelle

“…BACKGROUND: A key end point of early cancer clinical trials is the assessment of toxicities and their possible association with new experimental drugs…”
Get full text

Subtle Mutational Changes in the SU Protein of a Natural Feline Leukemia Virus Subgroup A Isolate Alter Disease Spectrum by CHANDHASIN, Chandtip, COAN, Patricia N, LEVY, Laura S

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Distinctive receptor binding properties of the surface glycoprotein of a natural feline leukemia virus isolate with unusual disease spectrum by Bolin, Lisa L, Chandhasin, Chandtip, Lobelle-Rich, Patricia A, Albritton, Lorraine M, Levy, Laura S

“…Feline leukemia virus (FeLV)-945, a member of the FeLV-A subgroup, was previously isolated from a cohort of naturally infected cats. An unusual multicentric…”
Get full text

Unique Long Terminal Repeat and Surface Glycoprotein Gene Sequences of Feline Leukemia Virus as Determinants of Disease Outcome by CHANDHASIN, Chandtip, COAN, Patricia N, PANDREA, Ivona, GRANT, Chris K, LOBELLE-RICH, Patricia A, PUETTER, Adriane, LEVY, Laura S

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation by Gatza, Michael L., Chandhasin, Chandtip, Ducu, Razvan I., Marriott, Susan J.

“…It is estimated that 15% of all cancers are etiologically linked to viral infection. Specific cancers including adult T‐cell leukemia, hepatocellular…”
Get full text

NIMG-28. VALIDATION OF MODIFIED RESPONSE ASSESSMENT IN NEURO ONCOLOGY (mRANO) DETERMINED PFS AS A STRONG PREDICTOR OF OVERALL SURVIVAL IN RECURRENT GLIOBLASTOMA TREATED WITH A TARGETED IMMUNOTOXIN by Ellingson, Benjamin, Chandhasin, Chandtip, Coello, Melissa, Merchant, Nina, Merchant, Fahar

“…Abstract INTRODUCTION The current study compared the modified response assessment in neuro-oncology (mRANO)(1), iRANO (2), and standard RANO criteria (3) as…”
Get full text

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors by Kurzrock, Razelle, Gabrail, Nash, Chandhasin, Chandtip, Moulder, Stacy, Smith, Carrie, Brenner, Andrew, Sankhala, Kamalesh, Mita, Alain, Elian, Kelly, Bouchard, Danielle, Sarantopoulos, John

“…GRN1005 is a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide, angiopep-2, that targets the low-density lipoprotein…”
Get full text

Abstract 2128: TACH101, a first-in-class pan inhibitor of KDM4 histone lysine demethylases by Yoo, Sanghee, Chandhasin, Chandtip, Rosario, Joselyn R. Del, Chen, Young K., Stafford, Jeff, Quake, Stephen, Perabo, Frank, Clarke, Michael F.

“…Abstract Background: Alterations in epigenetic control can cause defective post-translational histone modification and dysregulation of gene activity leading…”
Get full text

Pharmacologic characterization of TACH101, a first-in-class KDM4 inhibitor for development as a cancer therapeutic by Yoo, Sanghee, Chandhasin, Chandtip, Del Rosario, Joselyn, Chen, Young K, Stafford, Jeffrey, Perabo, Frank, Clarke, Michael F.

“…Abstract only e15067 Background: The histone Lysine (K) Demethylase 4 family, KDM4 family, is involved in nuclear functions such as programming development,…”
Get full text

Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4 by Chandhasin, Chandtip, Yoo, Sanghee, Del Rosario, Joselyn, Chen, Young K, Stafford, Jeffrey, Perabo, Frank, Clarke, Michael F.

“…Abstract only 3105 Background: The KDM4 family of histone lysine demethylases consists of four main isoforms (KDM4A, B, C, D), all of which have been…”
Get full text

TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase by Chandhasin, Chandtip, Dang, Van, Perabo, Frank, Del Rosario, Joselyn, Chen, Young K., Filvaroff, Ellen, Stafford, Jeffrey A., Clarke, Michael

“…Histone lysine demethylase 4 (KDM4) is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by…”
Get full text

Inhibition of cancer stem cells with TACH101, a first-in-class inhibitor of KDM4 histone lysine demethylase by Perabo, Frank, Chandhasin, Chandtip, Dang, Van, Del Rosario, Joselyn, Chen, Young K, Filvaroff, Ellen, Stafford, Jeffrey, Quake, Stephen, Clarke, Michael F.

“…e15105 Background: Cancer stem cells (CSCs) are believed to be responsible for both therapy resistance and metastasis. Until now, these resistant CSCs have not…”
Get full text

Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial by Sampson, John H, Singh Achrol, Achal, Aghi, Manish K, Bankiewicz, Krystof, Bexon, Martin, Brem, Steven, Brenner, Andrew, Chandhasin, Chandtip, Chowdhary, Sajeel, Coello, Melissa, Ellingson, Benjamin M, Floyd, John R, Han, Seunggu, Kesari, Santosh, Mardor, Yael, Merchant, Fahar, Merchant, Nina, Randazzo, Dina, Vogelbaum, Michael, Vrionis, Frank, Wembacher-Schroeder, Eva, Zabek, Miroslaw, Butowski, Nicholas

“…Abstract Background MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is…”
Get full text

Farnesyltransferase inhibitors: where are we now? by Tsimberidou, Apostolia Maria, Chandhasin, Chandtip, Kurzrock, Razelle

“…Farnesyltransferase inhibitors (FTIs) target multiple pathways implicated in the pathogenesis of solid and hematologic malignancies. Novel preclinical and…”
Get more information

Abstract P086: Identification of pharmacodynamic and sensitivity biomarkers for TACH101, a pan-inhibitor of KDM4 histone lysine demethylase by Perabo, Frank, Yoo, Sanghee, Chandhasin, Chandtip, Rosario, Joselyn Del, Chen, Young K., Filvaroff, Ellen, Stafford, Jeffrey A., Quake, Stephen, Clarke, Michael F.

“…Abstract Background: TACH101 is a novel, selective and potent inhibitor of KDM4 in development for advanced cancers. KDM4 plays a key role in epigenetic…”
Get full text

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer by NAING, Aung, KURZROCK, Razelle, ROHREN, Eric, NG, Chaan, CHANDHASIN, Chandtip, LORUSSO, Patricia, BURGER, Angelika, GUPTA, Sachin, XIUDONG LEI, BUSAIDY, Naifa, HONG, David, CHEN, Helen X, DOYLE, Lawrence A, HEILBRUN, Lance K

“…Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism…”
Get full text